How the Human Genome Can Predict Response to Hepatitis C Therapy

详细信息    查看全文

• 作者：Alexander J. Thompson (1)
  Jacques Fellay (2)
  John G. McHutchison (1)
  
• 关键词：HCV ; IL28B ; IFN ; α ; IFN ; λ ; GWAS ; Polymorphism
• 刊名：Current Hepatitis Reports
• 出版年：2010
• 出版时间：February 2010
• 年：2010
• 卷：9
• 期：1
• 页码：1-8
• 全文大小：250KB
• 参考文献：1. McHutchison JG, Lawitz EJ, Shiffman ML, et al.: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-93. CrossRef
  2. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65. CrossRef
  3. Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5 Suppl 1):S237–S244. CrossRef
  4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-55.
  5. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-271. CrossRef
  6. Conjeevaram HS, Fried MW, Jeffers LJ, et al.: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-77. CrossRef
  7. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al.: Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009, 360:257-67. CrossRef
  8. Liu CH, Liu CJ, Lin CL, et al.: Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-269. CrossRef
  9. Dev AT, McCaw R, Sundararajan V, et al.: Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002, 36:1259-265. CrossRef
  10. ?-Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-01. / This article was the first GWAS description of the role of IL28B genetic variation in the response to pegIFN and RBV therapy. CrossRef
  11. ?-Tanaka Y, Nishida N, Sugiyama M, et al.: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-109. / This GWAS confirmed the role of IL28B genetic variation in the response to pegIFN and RBV therapy in a Japanese population. CrossRef
  12. ?-Suppiah V, Moldovan M, Ahlenstiel G, et al.: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-104. / This GWAS confirmed the role of IL28B genetic variation in the response to pegIFN and RBV therapy in an Australian/European population. CrossRef
  13. Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 2008, 299:1335-344. CrossRef
  14. Morgan TR, Lambrecht RW, Bonkovsky HL, et al.: DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008, 49:548-56. CrossRef
  15. Welzel TM, Morgan TR, Bonkovsky HL, et al.: Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009, 49:1847-858. CrossRef
  16. Airoldi A, Zavaglia C, Silini E, et al.: Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C. Eur J Immunogenet 2004, 31:259-65. CrossRef
  17. Constantini PK, Wawrzynowicz-Syczewska M, Clare M, et al.: Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-12. CrossRef
  18. Dai CY, Chuang WL, Chang WY, et al.: Tumor necrosis factor-alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006, 193:98-01. CrossRef
  19. Schiemann U, Glas J, Torok P, et al.: Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 2003, 68:1-. CrossRef
  20. Vidigal PG, Germer JJ, Zein NN: Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002, 36:271-77. CrossRef
  21. Yee LJ, Tang J, Gibson AW, et al.: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-12. CrossRef
  22. Yu ML, Dai CY, Chiu CC, et al.: Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003, 59:35-0. CrossRef
  23. Su X, Yee LJ, Im K, et al.: Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 2008, 49:184-91. CrossRef
  24. Hijikata M, Ohta Y, Mishiro S: Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000, 43:124-27. CrossRef
  25. Suzuki F, Arase Y, Suzuki Y, et al.: Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004, 11:271-76. CrossRef
  26. Bonkovsky HL, Naishadham D, Lambrecht RW, et al.: Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006, 131:1440-451. CrossRef
  27. ?-Thomas DL, Thio CL, Martin MP, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-01. / This paper identified a role for the IL28B SNP, rs 12979860, in spontaneous clerance of HCV. CrossRef
  28. Kotenko SV, Gallagher G, Baurin VV, et al.: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-7. CrossRef
  29. Sheppard P, Kindsvogel W, Xu W, et al.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-8. CrossRef
  30. Ank N, West H, Paludan SR: IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006, 26:373-79. CrossRef
  31. Uze G, Monneron D: IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007, 89:729-34. CrossRef
  32. Witte K, Gruetz G, Volk HD, et al.: Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009, 10:702-14. CrossRef
  33. Marcello T, Grakoui A, Barba-Spaeth G, et al.: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-898. CrossRef
  34. Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79:3851-854. CrossRef
  35. Shiffman ML, Lawitz E, Zaman A, et al.: PEG-IFN-λ: antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection. J Hepatol 2009, 50 (Suppl. 1):s237(A643).
  
• 作者单位：Alexander J. Thompson (1)
  Jacques Fellay (2)
  John G. McHutchison (1)
  
  1. Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC, 27715, USA
  2. Institute for Genome Sciences & Policy Center for Human Genome Variation, Duke University, Durham, NC, 27708, USA
  

文摘

It has long been suspected that host genetic factors influenced treatment outcome of hepatitis C virus (HCV) infection. Three independent genome-wide association studies have recently identified genetic variation in the IL28B gene (coding for IFN-λ3) that determines the outcome of interferon-α-based therapy for patients with genotype 1 chronic hepatitis C infection. These discoveries confirm the potential for a pharmacogenomics approach to personalizing anti-HCV treatment.